KR101862172B1 - Composition for improving blood circulation containing dihydrodaidzein - Google Patents
Composition for improving blood circulation containing dihydrodaidzein Download PDFInfo
- Publication number
- KR101862172B1 KR101862172B1 KR1020100084831A KR20100084831A KR101862172B1 KR 101862172 B1 KR101862172 B1 KR 101862172B1 KR 1020100084831 A KR1020100084831 A KR 1020100084831A KR 20100084831 A KR20100084831 A KR 20100084831A KR 101862172 B1 KR101862172 B1 KR 101862172B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- blood circulation
- platelet aggregation
- thrombogenesis
- delete
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000017531 blood circulation Effects 0.000 title claims abstract description 26
- JHYXBPPMXZIHKG-CYBMUJFWSA-N Dihydrodaidzein Natural products C1=CC(O)=CC=C1[C@@H]1C(=O)C2=CC=C(O)C=C2OC1 JHYXBPPMXZIHKG-CYBMUJFWSA-N 0.000 title description 3
- JHYXBPPMXZIHKG-UHFFFAOYSA-N dihydrodaidzein Chemical compound C1=CC(O)=CC=C1C1C(=O)C2=CC=C(O)C=C2OC1 JHYXBPPMXZIHKG-UHFFFAOYSA-N 0.000 title description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000035602 clotting Effects 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims 2
- 230000036541 health Effects 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 6
- 208000008589 Obesity Diseases 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 235000020824 obesity Nutrition 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 다이하이드로다이드제인을 유효성분으로 함유하는 혈액 순환 개선용 조성물에 관한 것으로, 보다 상세하게는 상기 조성물은 다이하이드로다이드제인을 함유하여 혈소판 응집 및 혈전생성을 억제함으로써 혈액 순환 개선 효과가 우수하고, 비만 상태를 개선시키며, 당뇨 및 고질혈증 등의 치료 또는 예방에 효과적인 혈액 순환 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving blood circulation comprising a dihydroididase as an active ingredient, and more particularly, to a composition for improving blood circulation by containing a dihydroididase and inhibiting platelet aggregation and thrombus formation, , Which improves obesity and is effective for the treatment or prevention of diabetes and hyperlipidemia.
Description
본 발명은 다이하이드로다이드제인(DHD: dihydrodaidzein)을 유효성분으로 함유하는 혈액 순환 개선용 조성물에 관한 것으로, 보다 상세하게는 상기 조성물은 다이하이드로다이드제인을 함유하여 혈소판 응집 및 혈전생성을 억제함으로써 혈액 순환 개선 효과가 우수하고, 비만 상태를 개선시키며, 당뇨 및 고질혈증 등의 치료 또는 예방에 효과적인 혈액 순환 개선용 조성물에 관한 것이다.
The present invention relates to a composition for improving blood circulation comprising dihydrodaidzein (DHD) as an active ingredient, and more particularly, to a composition for improving blood circulation comprising a dihydroidide agent to inhibit platelet aggregation and thrombogenesis To improve a blood circulation, to improve an obesity state, and to be effective for treatment or prevention of diabetes and hyperlipidemia.
다이하이드로다이드제인은 콩의 주요 이소플라본(isoflavone) 중 하나인 다이드제인이 체내에 흡수되어 대사되는 과정 중에 생성되는 대사체 중 하나로, 콩과(leguminosae) 식물을 특정 미생물로 발효하거나 화학적으로 합성하여 제조할 수 있다. 다이하이드로다이드제인은 이소플라보노이드(isoflavonoid)의 일종으로 노르아드레날린(noradrenaline)에 의해 유도되는 혈관 수축 작용을 억제하고 혈관 벽의 신생 내막(neointima) 형성을 억제하는 효과가 있어 심장 질환에 효과가 있을 것으로 보고되어 있으나(British Journal of Pharmacology (2001) 133, 595-605; European Journal of Pharmacology 548 (2006) 123-128), 아직까지 다이하이드로제인이 혈전 생성 억제나 혈소판 응집 억제를 통하여 혈액 순환을 개선하는 효과가 있음을 구체적으로 밝힌 사실은 없다.Dihydroidide is one of the major metabolites produced during the metabolism of diidzein, which is one of the major isoflavones of soybean, in the body. It is a kind of microorganism that ferment leguminosae plants as specific microorganisms or chemically Can be synthesized. Dihydroidideine is a type of isoflavonoid that inhibits noradrenaline-induced vasoconstriction and inhibits the formation of neointima in the vascular wall, which is effective for heart disease (2001) 133, 595-605, European Journal of Pharmacology 548 (2006) 123-128), yet dihydrogenase has been shown to improve blood circulation through inhibition of thrombus formation or inhibition of platelet aggregation There is no concrete fact that the effect of
식생활 패턴의 변화에 따라, 현대인은 지방질 섭취량은 많아짐에도 운동량은 상대적으로 부족하며, 각종 스트레스를 받으며 살아가고 있다. 이러한 식생활의 변화로 인해, 고혈압, 동맥경화 또는 혈액 순환 장애 등의 질병이 증가하는 추세이다. 특히, 혈액 순환 장애는 기억력 감퇴, 무기력, 집중력의 약화 및 만성 피로 등의 증상을 유발하는 것으로 알려져 있다. According to the change of dietary pattern, modern people have a relatively low amount of exercise and a lot of stress. Due to such dietary changes, diseases such as hypertension, arteriosclerosis or blood circulation disorder are increasing. In particular, blood circulation disorders are known to cause symptoms such as memory decline, lethargy, weakening of concentration and chronic fatigue.
혈액 순환이란 체내의 혈액이 일정한 방향으로 유동하는 현상을 말하고, 혈액 순환 장애는 혈관이 탄력을 잃고 내벽에 콜레스테롤 등이 침착되어 혈관 내부가 좁아져 혈액 순환이 원활하게 이루어지지 않는 현상을 의미한다. Blood circulation refers to the phenomenon that the blood in the body flows in a certain direction. The blood circulation disorder means that the blood circulation is not smooth due to the narrowing of the blood vessel due to the loss of elasticity of blood vessels and deposition of cholesterol on the inner wall.
혈액 순환 장애로 인해 유발되는 질병으로는, 고지혈증, 동맥경화, 심근경색 또는 뇌혈전증 등과 같은 심혈관계 질환이 있다. 심혈관계 질병 중에서도 고혈압, 동맥경화, 심장병 또는 뇌졸증 등은 노령층에서는 사망의 가장 큰 원인 중 하나로 꼽히고 있다. Diseases caused by impaired blood circulation include cardiovascular diseases such as hyperlipidemia, arteriosclerosis, myocardial infarction or cerebral thrombosis. Among cardiovascular diseases, hypertension, arteriosclerosis, heart disease or stroke are among the major causes of death in the elderly.
이처럼 혈액 순환 장애를 방치할 경우에는 정상적인 생활을 유지하는 데에 어려움을 주게 되고, 심할 경우에는 다양한 형태의 질환으로 발전되어 사망에 이를 수도 있다. 따라서, 혈액 순환 장애로 인한 질병에 대한 치료보다는 예방이 중요하다고 볼 수 있다.
If the blood circulation disorder is neglected, it will be difficult to maintain normal life, and in severe cases, it may develop into various types of diseases and lead to death. Therefore, prevention is more important than treatment for diseases caused by blood circulation disorder.
이에 본 발명자들은 다이하이드로다이드제인이 혈소판 응집 및 혈전생성을 억제하는 효과를 갖는 것을 확인하고 본 발명을 완성하게 되었다.Thus, the inventors of the present invention confirmed that dihydroididase inhibits platelet aggregation and thrombogenesis, and completed the present invention.
따라서, 본 발명의 목적은 혈소판 응집 및 혈전생성을 억제하는 효과가 우수한 혈액 순환 개선용 조성물을 제공하는 것이다.
Accordingly, an object of the present invention is to provide a composition for improving blood circulation which is excellent in inhibiting platelet aggregation and thrombus formation.
상기 목적을 달성하기 위하여, 본 발명에서는 다이하이드로다이드제인을 유효성분으로 함유하는 혈액 순환 개선용 조성물을 제공한다.
In order to achieve the above object, the present invention provides a composition for improving blood circulation comprising dihydroidide as an active ingredient.
본 발명에 의한 혈액 순환 개선용 조성물은 다이하이드로다이드제인을 유효성분으로 함유함으로써 혈소판 응집을 억제하여 혈전생성을 저해하고, 혈액 순환을 개선하는 효과가 있으며, 콜레스테롤의 증가를 억제하여 혈액 순환 개선에 효과적이며, 비만, 당뇨 및 고지혈증 등의 치료 또는 예방에 효과가 있는 조성물을 제공할 수 있어 식품 및 의약 분야에서 다양하게 활용 가능하다.
The composition for improving blood circulation according to the present invention inhibits platelet aggregation by inhibiting platelet aggregation by inhibiting platelet aggregation and improving blood circulation by containing dihydroididase as an active ingredient and has an effect of inhibiting increase of cholesterol and improving blood circulation And it is possible to provide a composition which is effective for the treatment or prevention of obesity, diabetes and hyperlipidemia, and thus can be used in various fields in food and medicine fields.
도 1은 다이하이드로다이드제인을 경구 투여 시 혈전 생성 억제 효능을 나타낸 그래프이다.BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a graph showing the effect of inhibiting thrombogenesis upon oral administration of dihydrolidase. Fig.
본 발명은 하기 화학식 1로 표현되는 다이하이드로다이드제인을 유효성분으로 함유하는 혈액 순환 개선용 조성물에 관한 것이다:The present invention relates to a composition for improving blood circulation comprising, as an active ingredient, a dihydroididase represented by the following formula 1:
본 발명에 의한 조성물은 상기 다이하이드로제인을 조성물 총 중량에 대하여 0.01∼50 중량%로 함유할 수 있다.
The composition according to the present invention may contain 0.01 to 50% by weight of the dihydrogenase, based on the total weight of the composition.
본 발명에 의한 피부 미용 조성물은 혈소판 응집을 억제하여 혈전생성을 저해하고, 콜레스테롤의 증가를 억제하여 혈액과 간의 지질을 감소시켜 혈액 순환 개선에 효과적이며, 비만, 당뇨, 뇌졸증, 뇌출혈, 동맥경화, 고혈압, 빈혈, 편두통 또는 고지혈증 등의 혈관 질환 치료 또는 예방에 효과적으로 사용될 수 있다.The skin-care composition according to the present invention inhibits platelet aggregation and inhibits thrombogenesis. The composition reduces blood and liver lipid by inhibiting the increase of cholesterol, and is effective for improving blood circulation, and is useful for obesity, diabetes, cerebral hemorrhage, Hypertension, anemia, migraine, or hyperlipemia.
본 발명의 일실시예에서, 상기 조성물은 혈액 순환 개선용 식품 첨가제, 기능성 식품 또는 건강식품 등을 제공한다. 구체적으로는, 상기 조성물은 혈관 질환의 치료 또는 예방에 효과적인 건강식품 조성물일 수 있다. 상기 혈관 질환은, 예를 들어, 비만, 당뇨, 뇌졸증, 뇌출혈, 동맥경화, 고혈압, 빈혈, 편두통 또는 고지혈증 등을 포함한다. In one embodiment of the present invention, the composition provides a food additive for improving blood circulation, a functional food or a health food. Specifically, the composition may be a health food composition effective for the treatment or prevention of vascular diseases. Such vascular diseases include, for example, obesity, diabetes, stroke, cerebral hemorrhage, arteriosclerosis, hypertension, anemia, migraine or hyperlipidemia.
또한 본 발명의 일실시예에서, 상기 조성물은 발효유, 치즈, 요구르트, 주스, 생균제제 및 건강보조식품 등으로 가공될 수 있으며, 그 외 다양한 식품 첨가제의 형태로 사용될 수 있다. In addition, in one embodiment of the present invention, the composition may be processed into fermented milk, cheese, yogurt, juice, probiotics, health supplements and the like, and may be used in various other food additives.
상기 조성물은, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 주 효과에 상승 효과를 줄 수 있는 다른 성분 등을 함유할 수 있다. 예를 들어, 물성 개선을 위하여 향료, 색소, 살균제, 산화방지제, 방부제, 보습제, 점증제, 무기염류, 유화제 및 합성 고분자 물질 등의 첨가제를 더 포함할 수 있다. 그 외에도, 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당 및 해초 엑기스 등의 보조 성분을 더 포함할 수도 있다. 상기 성분들은 제형 또는 사용 목적에 따라서 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 그 첨가량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. 예를 들어, 상기 성분들의 첨가량은, 조성물 전체 중량을 기준으로, 0.01∼5 중량%, 보다 구체적으로는 0.01∼3 중량% 범위일 수 있다.The composition may contain other components or the like which can give a synergistic effect to the main effect within a range not impairing the intended main effect of the present invention. For example, additives such as perfume, coloring agent, bactericide, antioxidant, preservative, moisturizing agent, thickening agent, inorganic salt, emulsifier and synthetic polymer substance may be further added for improvement of physical properties. In addition, it may further contain auxiliary components such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides and seaweed extract. The above components may be mixed and selected without difficulty by those skilled in the art depending on the purpose of formulation or use, and the amount thereof may be selected within a range that does not impair the objects and effects of the present invention. For example, the amount of addition of the above components may range from 0.01 to 5% by weight, more specifically from 0.01 to 3% by weight, based on the total weight of the composition.
본 발명에 따른 조성물의 제형은 용액, 유화물, 점성형 혼합물, 타블렛, 분말 등의 다양한 형태일 수 있으며, 이는 단순 음용, 주사 투여, 스프레이 방식 또는 스퀴즈 방식 등의 다양한 방법으로 투여될 수 있다.
The composition according to the present invention may be in various forms such as a solution, an emulsion, a viscous mixture, a tablet, a powder, etc., and may be administered by various methods such as simple drinking, injection administration, spraying or squeezing.
또한 본 발명에 의한 조성물은 혈전생성 방지 및 콜레스테롤 억제 효능을 갖는 혈액 순환 개선용 약제학적 조성물일 수 있다. 구체적으로는, 상기 약제학적 조성물은 혈관 질환의 치료 또는 예방에 효과적인 약제학적 조성물일 수 있다. 상기 혈관 질환은, 예들 들어, 비만, 당뇨, 뇌졸증, 뇌출혈, 동맥경화, 고혈압, 빈혈, 편두통 또는 고지혈증을 포함한다. In addition, the composition of the present invention may be a pharmaceutical composition for preventing blood clot formation and improving blood circulation with cholesterol-inhibiting effect. Specifically, the pharmaceutical composition may be a pharmaceutical composition effective for the treatment or prevention of vascular diseases. Such vascular diseases include, for example, obesity, diabetes, stroke, cerebral hemorrhage, arteriosclerosis, hypertension, anemia, migraine or hyperlipidemia.
본 발명에 의한 조성물을 의약품에 적용할 경우에는 상기 조성물을 유효성분으로 하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제제화될 수 있으며, 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내 또는 피하 등으로 투여될 수 있다. When the composition according to the present invention is applied to medicines, it can be formulated into oral or parenteral dosage forms in the form of solid, semi-solid or liquid by adding an inorganic or organic carrier, which is commonly used as an active ingredient, , Parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally or subcutaneously.
상기 경구 투여를 위한 제재로서는 정제(錠劑), 환제(丸劑), 과립제(顆粒劑), 연·경 캡슐제, 산제, 세립제, 분제, 유탁제(乳濁濟), 시럽제, 펠렛제 등을 들 수 있다. 또한, 상기 비경구 투여를 위한 제재로는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제 또는 좌제(坐劑) 등을 들 수 있다. 본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제 또는 기타 상용하는 보조제를 적당히 사용할 수 있다.Examples of the agent for oral administration include tablets, pills, granules, soft capsules, powders, granules, powders, emulsions, syrups and pellets. . Examples of the parenteral administration agent include injections, drops, ointments, lotions, sprays, suspensions, emulsions or suppositories. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method. Surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspending agents and other adjuvants can be suitably used.
또한, 상기 활성성분의 투여량은 치료 받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있다. 일반적인 투여량은 0.001 mg/kg/일 내지 2,000 mg/kg/일, 보다 구체적으로는 0.1 mg/kg/일 내지 1,000 mg/kg/일이다.
In addition, the dosage of the active ingredient will depend on the age, sex, body weight of the subject to be treated, the particular disease or condition to be treated, the severity of the disease or condition, the route of administration and the judgment of the prescriber. Dosage determinations based on these factors are within the level of those skilled in the art. Typical dosages are from 0.001 mg / kg / day to 2,000 mg / kg / day, more specifically from 0.1 mg / kg / day to 1,000 mg / kg / day.
이하, 본 발명의 내용을 실시예 및 시험예를 통하여 보다 구체적으로 설명한다. 이들 실시예는 본 발명의 내용을 이해하기 위해 제시되는 것일 뿐 본 발명의 권리범위가 이들 실시예로 한정되는 것은 아니고, 당업계에서 통상적으로 주지된 변형, 치환 및 삽입 등을 수행할 수 있으며, 이에 대한 것도 본 발명의 범위에 포함된다.
Hereinafter, the present invention will be described more specifically with reference to examples and test examples. It is to be understood that the scope of the present invention is not limited to these embodiments and that variations, substitutions, and insertions conventionally known in the art can be carried out, And this is included in the scope of the present invention.
[시험예 1] 콜라겐에 의해 유도된 사람 혈소판 응집 억제 효과[Test Example 1] Collagen-induced inhibition of human platelet aggregation
에탄올 함량에 따른 추출물의 활성 차이를 비교하기 위하여 하기의 실험을 실시하였다. The following experiments were conducted to compare the differences in the activity of the extracts according to the ethanol content.
사람의 혈소판 농축 혈장(PRP: Platelet Rich Plasma)을 분리하기 위하여, 3.2% 구연산 나트륨(sodium citrate)을 항응고제로 하여 2 주일 이상 약물을 복용하지 않은 건강한 남성의 정맥으로부터 혈액을 채취하였다. 채혈된 혈액 150 g을 15 분간 원심 분리한 후, 상층액(PRP)을 얻고 잔사를 다시 원심분리하여 혈소판 결핍 혈장(PPP: platelet poor plasma)을 분리하였다. 분리된 PRP의 혈소판 수는 광학 현미경을 사용하여 세고, PRP를 PPP로 희석하여 1 ㎖당 3×108 개의 혈소판이 포함되도록 희석한 뒤에 실험에 사용하였다.To separate human platelet rich plasma (PRP), blood was collected from a healthy male's vein that was not taking the drug for more than 2 weeks with 3.2% sodium citrate as an anticoagulant. 150 g of the collected blood was centrifuged for 15 minutes, and the supernatant (PRP) was obtained and the residue was centrifuged again to separate the platelet poor plasma (PPP). Platelet counts of isolated PRP were counted using an optical microscope, PRP was diluted with PPP, diluted to contain 3 × 10 8 platelets per 1 ml, and then used in the experiment.
혈소판의 응집 활성은, 혈소판 응집계(lumi-aggregometer; Chrono-Log Co., USA)를 이용하여, 흡광도 변화를 통해 측정하였다. PRP에 다이하이드로다이드제인을 25, 50, 100 및 200 ㎍/ml씩 가하고 열혼합기(thermomixer)에서 10 분간 배양하였다. 배양한 PRP 495 ㎕를 실리콘이 코팅된 혈소판 응집계용 큐벳에 넣고 1 분간 선배양하여 37℃가 되도록 하였다. 그런 다음, 혈소판 응집 유발 시료인 콜라겐을 최대 응집을 일으키는 농도인 5 g/ml을 가하고, 이 후 5 분간 반응을 관찰하였으며, 그 결과를 하기 표 1에 나타내었다. 표 1의 혈소판 응집 억제율(%)은, 콜라겐만 처리한 대조군의 혈소판 응집 억제율을 0%로 했을 때의 비교값을 나타낸 것이다. The aggregation activity of the platelets was measured using a lumi-aggregometer (Chrono-Log Co., USA) by changing the absorbance. 25, 50, 100 and 200 / / ml of dihydrolidone were added to the PRP and cultured in a thermomixer for 10 minutes. The cultured PRP (495 ㎕) was placed in a cuvet coated with silicone coated platelet aggregation system and incubated for 1 minute at 37 캜. Then, a concentration of 5 g / ml, which is the maximum aggregation concentration, was added to collagen, which is a platelet aggregation-inducing sample, and the reaction was observed for 5 minutes. The results are shown in Table 1 below. The platelet aggregation inhibition rate (%) shown in Table 1 represents the comparison value when the platelet aggregation inhibition rate of the control group treated with only collagen is 0%.
표 1의 결과에서, 다이하이드로다이드제인은 농도의존적으로 혈소판 응집 억제효능을 가짐을 확인할 수 있었다.
From the results shown in Table 1, it was confirmed that the dihydrolidase inhibitor has a platelet aggregation inhibitory effect in a concentration-dependent manner.
[시험예 2] SD 래트(Sprague Dawley rat)를 이용한 정맥혈전생성 억제 효과 관찰[Test Example 2] Inhibition of venous blood formation by SD rat (Sprague Dawley rats)
다이하이드로다이드제인을 실제 섭취하였을 경우 생체 내에서 혈전생성억제 효능이 있는지 알아보기 위하여, 체중 220∼250 g의 숫컷 SD 래트를 대상으로 정맥혈전생성 억제 효능 시험을 실시하였다. In order to investigate the effect of dihydroididadein in vivo to inhibit thrombogenesis in vivo, male SD rats weighing 220 to 250 g were tested for the effect of inhibiting venous blood formation.
SD 래트에 각각 25 및 50 g/ml의 다이하이드로다이드제인을 식염수(saline) 300 ㎕에 용해시켜 경구로 투여한 뒤, 1 시간 동안 방치하였다. 1 시간 후, 펜토바비탈나트륨(sodium pentobarbital) 50 mg/kg을 복강투여하여 전신 마취시킨 후, 개복하고 후대정맥(caudal vena cava)이 잘 보이도록 지방조직을 걷어내었다. 지방조직을 걷어낼 때 주변의 혈관이 손상되지 않도록 주의하였다. 5% FeCl3 용액을 필터페이퍼(filter paper)에 적셔 후대정맥 위에 5 분간 적용한 다음 제거하였다. 30 분 후, 혈전을 함유하고 있는 후대정맥을 12 mm 길이로 결찰한 다음 절제하였다. 식염수에 혈전 덩어리를 떼어낸 후 수분은 제거하고 무게를 측정하여 각 시험군을 비교하였고, 그 결과를 도 1에 나타내었다. SD rats were orally administered with 25 and 50 g / ml of dihydrolidase dissolved in 300 ㎕ of saline, respectively, and left for 1 hour. One hour later, 50 mg / kg of sodium pentobarbital was administered intraperitoneally, followed by general anesthesia, and then the adipose tissue was removed so that the caudal vena cava was visible. When removing the fat tissue, care was taken not to damage the surrounding blood vessels. 5% FeCl 3 solution was wetted on filter paper and applied on the vena cava for 5 minutes and then removed. After 30 minutes, the vena cava containing thrombus was ligated to a length of 12 mm and then resected. The blood clots were removed from the saline solution, the water was removed, and the weights were measured. The test groups were compared and the results are shown in FIG.
도 1의 결과에서, 다이하이드로다이드제인 25 및 50 mg/kg을 경구 투여하였을 때, 50 mg/kg에서 유의적으로 혈전 생성이 억제되는 것을 확인할 수 있었다. 이를 통해 다이하이드로다이드제인이 우수한 항혈전제로 작용하였음을 알 수 있다.
1, it was confirmed that thrombogenesis was significantly inhibited at 50 mg / kg when 25 and 50 mg / kg of dihydrolidase were orally administered. It can be seen that dihydroididzein acts as an excellent antithrombotic agent.
본 발명에 의한 다이하이드로다이드제인 함유 조성물은 하기와 같이 여러 가지 제형으로 응용 가능하지만, 이에 한정되는 것은 아니다.
The dihydroididase-containing composition according to the present invention can be applied to various formulations as described below, but is not limited thereto.
[제형예 1] 연질 캡슐의 제조[Formulation Example 1] Preparation of soft capsules
다이하이드로다이드제인 264 mg, 비타민 E 30 mg, 비타민 C 30 mg, 팜유 6 mg, 식물성 경화유 27 mg, 황납 13 mg 및 레시틴 30 mg을 혼합하고, 통상의 방법에 따라 혼합하여 연질캡슐 충진액을 제조하였다. 1 캡슐당 400 ㎎씩 충진하여 연질캡슐을 제조하였다. 그리고, 상기와 별도로 젤라틴 66 중량%, 글리세린 24 중량% 및 솔비톨액 10 중량%로 연질캡슐시트를 제조하고 상기 충진액을 충진시켜 본 발명에 따른 조성물 400 mg이 함유된 연질캡슐을 제조하였다.
264 mg of dihydroidide, 30 mg of vitamin E, 30 mg of vitamin C, 6 mg of palm oil, 27 mg of vegetable hardening oil, 13 mg of yellow powder and 30 mg of lecithin were mixed and mixed according to a usual method to prepare a soft capsule filling liquid . 400 mg per capsule was filled to prepare a soft capsule. Separately from the above, a soft capsule sheet was prepared from 66% by weight of gelatin, 24% by weight of glycerin and 10% by weight of sorbitol, and filled with the filling solution to prepare a soft capsule containing 400 mg of the composition of the present invention.
[제형예 2] 정제의 제조[Formulation Example 2] Preparation of tablet
다이하이드로다이드제인 80 mg, 비타민 E 9 mg, 비타민 C 9 mg, 갈락토올리고당 200 ㎎, 유당 60 ㎎ 및 맥아당 140 ㎎을 혼합하고 유동층 건조기를 이용하여 과립한 후 당 에스테르(sugar ester) 6 ㎎을 첨가하였다. 이들 조성물 504 mg을 통상의 방법으로 타정하여 정제를 제조하였다.
After mixing 80 mg of dihydroidide, 9 mg of vitamin E, 9 mg of vitamin C, 200 mg of galactooligosaccharide, 60 mg of lactose and 140 mg of maltose, granulated using a fluid bed drier, 6 mg of sugar ester Was added. 504 mg of these compositions were tabletted by a conventional method to prepare tablets.
[제형예 3] 드링크제의 제조[Formulation Example 3] Preparation of Drinking Agent
다이하이드로다이드제인 80 mg, 비타민 E 9 mg, 비타민 C 9 mg, 포도당 10 g, 구연산 0.6 g, 및 액상 올리고당 25 g을 혼합한 후 정제수 300 ㎖를 가하여 각 병에 200 ㎖씩 되도록 충진하였다. 병에 충진한 후 130℃에서 4∼5 초간 살균하여 음료를 제조하였다.
After mixing 80 mg of dihydroidide, 9 mg of vitamin E, 9 mg of vitamin C, 10 g of glucose, 0.6 g of citric acid and 25 g of liquid oligosaccharide, 300 ml of purified water was added and 200 ml of each solution was filled in each bottle. And then sterilized at 130 DEG C for 4 to 5 seconds to prepare a beverage.
[제형예 4] 과립의 제조[Formulation Example 4] Preparation of granules
다이하이드로다이드제인 80 mg, 비타민 E 9 mg, 비타민 C 9 mg, 무수결정 포도당 250 ㎎ 및 전분 550 ㎎을 혼합하고, 유동층 과립기를 사용하여 과립으로 성형한 후 포에 충진하여 제조하였다.
80 mg of dihydroidide, 9 mg of vitamin E, 9 mg of vitamin C, 250 mg of anhydrous crystalline glucose, and 550 mg of starch were mixed and granulated into granules using a fluidized bed granulator and filled in a capsule.
본 발명이 속한 분야에서 통상의 지식을 가진 자라면 상기 내용을 바탕으로 본 발명의 범주 내에서 다양한 응용 및 변형을 행하는 것이 가능할 것이다.
Those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.
Claims (10)
상기 조성물은 혈소판 응집, 혈전 생성, 또는 상기 혈소판 응집 및 혈전 생성 둘 모두를 억제하는 것을 특징으로 하는, 약학 조성물.
An antihypertensive pharmaceutical composition comprising dihydroidide as an active ingredient,
Wherein said composition inhibits platelet aggregation, thrombogenesis, or both said platelet aggregation and thrombogenesis.
The pharmaceutical composition according to claim 1, wherein the composition is used for treating, alleviating or alleviating thrombosis of the brain or vein caused by blood circulation disorder caused by blood clot formation.
상기 조성물은 혈소판 응집, 혈전 생성, 또는 상기 혈소판 응집 및 혈전 생성 둘 모두를 억제하는 것을 특징으로 하는, 건강기능식품 조성물.
A health functional food composition for diabetic neuropathy containing dihydroidide as an effective ingredient,
Wherein said composition inhibits platelet aggregation, thrombogenesis, or both said platelet aggregation and thrombogenesis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100084831A KR101862172B1 (en) | 2010-08-31 | 2010-08-31 | Composition for improving blood circulation containing dihydrodaidzein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100084831A KR101862172B1 (en) | 2010-08-31 | 2010-08-31 | Composition for improving blood circulation containing dihydrodaidzein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120020904A KR20120020904A (en) | 2012-03-08 |
| KR101862172B1 true KR101862172B1 (en) | 2018-05-30 |
Family
ID=46129413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100084831A KR101862172B1 (en) | 2010-08-31 | 2010-08-31 | Composition for improving blood circulation containing dihydrodaidzein |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101862172B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822090B (en) * | 2017-02-09 | 2020-08-28 | 中国科学院昆明动物研究所 | Application of 3,4, 7-trihydroxy isoflavone or 3-methoxy daidzein in preparing medicine for inhibiting platelet aggregation and thrombosis |
-
2010
- 2010-08-31 KR KR1020100084831A patent/KR101862172B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120020904A (en) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11197903B2 (en) | Composition containing a bean extract for improving blood circulation and vascular health and method for improving blood circulation and vascular health | |
| US8962594B2 (en) | Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia | |
| US10576057B2 (en) | Methods for treating muscle wasting and degeneration diseases | |
| US9694045B2 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same | |
| JP6370302B2 (en) | Composition comprising catechin bioavailability enhancer containing γ-cyclodextrin and catechin | |
| KR101997060B1 (en) | Composition for prevention or treatment of muscular disorder, or improvement of muscular functions comprising fermented deer antler | |
| KR101055337B1 (en) | Blood circulation improvement composition containing five extracts or fractions thereof as an active ingredient | |
| CA3001472A1 (en) | Composition comprising lactobacillus plantarum 2830 (ecgc 13110402) | |
| KR101862172B1 (en) | Composition for improving blood circulation containing dihydrodaidzein | |
| KR101886350B1 (en) | Composition containing triterpenoid saponin extracted from the root of Camellia sinensis | |
| KR20170023910A (en) | Pharmaceutical Compositions for Prevention or Treatment of nonalcoholic fatty liver disease Comprising Quercetin-3-O-glucoside | |
| KR100805865B1 (en) | Anti-thrombus agent comprising extract of herbal mixture | |
| KR101897770B1 (en) | Pharmaceutical composition for use in preventing or treating dyslipidemia containing extract of radish sprouts as an active ingredient | |
| KR20050042302A (en) | Composition for the prevention or treatment of diseases associated with angiogenesis comprising the extract of cnidium officinale makino or the fraction therefrom | |
| KR20160066253A (en) | Composition for preventing or improving metabolic syndrome containing icariside B2 | |
| KR101536231B1 (en) | Composition for Preventing or Treating Insulin Resistance or Insulin Resistance-Related Diseases Comprising Eleutheroside E | |
| KR101218458B1 (en) | Composition for Prevention or Treatment of Circulatory Disorder Comprising the Nootkatone | |
| KR102674622B1 (en) | Composition for preventing, improving or treating Sarcopenia comprising deferoxamine | |
| KR20140104090A (en) | A pharmaceutical composition for treating and preventing fatty liver diseases containing curcumin as an active ingredient | |
| KR20190097332A (en) | Composition for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising extract of Cornus officinalis as effective component | |
| JP2010241725A (en) | Hyaluronic acid production promoter | |
| Barseghian El-Farra et al. | Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia. | |
| KR20220040617A (en) | Composition for inhibiting gout comprising mixture of Scutellaria baicalensis extract and nelumbinis folium extract as active ingredient | |
| KR20240070312A (en) | Composition for preventing, improving or treating muscle disease comprising vincamine | |
| KR101596123B1 (en) | Novel azaindole compounds for inhibiting diacylglycerol acyltransferase 2 and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017101001951; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170424 Effective date: 20180430 |
|
| S901 | Examination by remand of revocation | ||
| GRNO | Decision to grant (after opposition) | ||
| GRNT | Written decision to grant |